Frequency of Bone Marrow Toxicity by Using Pattern of Azathioprine in Inflammatory Bowel Disease Patients
Intestinal Research
;
: 244-250, 2012.
Article
Dans Coréen
| WPRIM
| ID: wpr-45087
ABSTRACT
BACKGROUND/AIMS:
The most important adverse effect of azathioprine (AZA) is bone marrow toxicity (BMT). Many physicians have preferred a gradual dose increment (GDI) policy for the prevention of BMT. The aim of this study was to evaluate the efficacy of GDI for the prevention of AZA-induced BMT in inflammatory bowel disease (IBD) patients.METHODS:
The medical records of IBD patients who received AZA in 6 university hospitals were reviewed. The patients were divided into two groups the GDI group (initial dose or =2 mg/kg).RESULTS:
A total of 308 patients were enrolled (male to female ratio, 12.3; mean age, 34.91+/-14.19 years; ulcerative colitis, 43.5%; Crohn's disease, 55.2%; and intermediate colitis, 1.3%). The overall incidence of BMT was 16.2% (50/308). BMT developed most frequently between fourth to eighth week (26%, 13/50). The rate of BMT of the non-GDI group was significantly higher than that of the GDI group (27.5%, 11/40 vs. 14.6%, 39/268, P=0.038). A multivariate analysis showed that the only factor related to BMT was a non-GDI policy (P=0.036; odds ratio, 2.41; 95% confidence interval, 1.06-5.49).CONCLUSIONS:
A GDI policy could be useful for reducing AZA-induced BMT in Korean IBD patients.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Azathioprine
/
Moelle osseuse
/
Maladies inflammatoires intestinales
/
Rectocolite hémorragique
/
Maladie de Crohn
/
Odds ratio
/
Dossiers médicaux
/
Incidence
/
Analyse multifactorielle
/
Colite
Type d'étude:
Etude d'étiologie
/
Etude d'incidence
/
Étude pronostique
Limites du sujet:
Femelle
/
Humains
langue:
Coréen
Texte intégral:
Intestinal Research
Année:
2012
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS